$Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML$

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Limited treatment options are available for patients with relapsed/refractory acute myeloid leukemia (R/R AML). We recently reported results from the phase 3 IDHENTIFY trial (NCT02577406) showing improved response rates and event-free survival with enasidenib monotherapy compared with conventional c...

Descripció completa

Dades bibliogràfiques
Autors principals:	Risueño, A, See, WL, Bluemmert, I, de Botton, S, DiNardo, CD, Fathi, AT, Schuh, AC, Montesinos, P, Vyas, P, Prebet, T, Gandhi, A, Hasan, M
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2024

Ítems similars

Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
per: Risueño, A, et al.
Publicat: (2023)

AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
per: DiNardo, CD, et al.
Publicat: (2022)

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
per: DiNardo, CD, et al.
Publicat: (2021)

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
per: De Botton, S, et al.
Publicat: (2022)

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
per: Dinardo, CD, et al.
Publicat: (2022)

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
per: DiNardo, CD, et al.
Publicat: (2021)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
per: de Botton, S, et al.
Publicat: (2022)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
per: DiNardo, CD, et al.
Publicat: (2021)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
per: Stein, EM, et al.
Publicat: (2017)

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
per: Stein, EM, et al.
Publicat: (2018)

Differentiation Syndrome in a Patient With NSCLC Harboring IDH2 Mutation Treated With Enasidenib: Case Report
per: Bhoomika Sukhadia, MD, et al.
Publicat: (2024-10-01)

A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AML)
per: Papayannidis, C, et al.
Publicat: (2021)

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
per: Vyas, P, et al.
Publicat: (2018)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
per: Ghayas C. Issa, et al.
Publicat: (2021-06-01)

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
per: Quek, L, et al.
Publicat: (2017)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
per: Lachowiez, C, et al.
Publicat: (2022)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
per: Desiree Kunadt, et al.
Publicat: (2022-09-01)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
per: Hills, R, et al.
Publicat: (2018)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
per: Stéphane deBotton, et al.
Publicat: (2021-09-01)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
per: Danielle Hammond, et al.
Publicat: (2023-09-01)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
per: P. Laskowska, et al.
Publicat: (2022-06-01)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
per: Stéphanie Mourad, et al.
Publicat: (2019-08-01)

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes
per: Vasiliki Papadopoulou, et al.
Publicat: (2023-12-01)

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context
per: Verónica Rey, et al.
Publicat: (2024-04-01)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
per: Bozena Kaminska, et al.
Publicat: (2019-03-01)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
per: DiNardo, C, et al.
Publicat: (2019)

P449: NOVEL, FIRST-IN-CLASS, SOMATIC IDH2 DELETION-INSERTION VARIANT C.516_518DELINSTGC CONFERS BORDERLINE PHENOTYPE AND DOES NOT SHOW SUSCEPTIBILITY TO ENASIDENIB IN-VITRO
per: L. Ruhnke, et al.
Publicat: (2022-06-01)

Research progress of IDH1 and IDH2 mutations in gliomas
per: Shan-shan ZHANG, et al.
Publicat: (2015-11-01)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
per: Ecmel Mehmetbeyoglu, et al.
Publicat: (2023-08-01)

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.
per: Jing-Han Wang, et al.
Publicat: (2015-01-01)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
per: Aniket Bhide, et al.
Publicat: (2023-08-01)

Ovarian juvenile granulosa cell tumors with Ollier’s disease in children with IDH1 gene somatic mutation
per: Jin Zhang, et al.
Publicat: (2023-05-01)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
per: James M. Cleary, et al.
Publicat: (2022-09-01)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
per: Lachowiez, CA, et al.
Publicat: (2023)

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
per: Amatangelo, MD, et al.
Publicat: (2017)

GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS
per: M. Yu. Prokudin, et al.
Publicat: (2020-09-01)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
per: Ali S. Haider, et al.
Publicat: (2023-04-01)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
per: Erika F. Rodriguez, et al.
Publicat: (2020-06-01)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
per: Lachowiez, CA, et al.
Publicat: (2022)

Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
per: Yu Yao, et al.
Publicat: (2013-01-01)